GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » Sale Of Business

ALLO (Allogene Therapeutics) Sale Of Business : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics Sale Of Business?

Allogene Therapeutics's sale of business for the three months ended in Dec. 2024 was $0.00 Mil. It means Allogene Therapeutics gained $0.00 Mil from selling business. Allogene Therapeutics's sale of business for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2024 ), Allogene Therapeutics gained the same money from selling business in Dec. 2024 ($0.00 Mil).

Allogene Therapeutics Sale Of Business Historical Data

The historical data trend for Allogene Therapeutics's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allogene Therapeutics Sale Of Business Chart

Allogene Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Business
Get a 7-Day Free Trial - - - - -

Allogene Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Allogene Therapeutics Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allogene Therapeutics Sale Of Business Related Terms

Thank you for viewing the detailed overview of Allogene Therapeutics's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Allogene Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » Sale Of Business
Comparable Companies
HUMA ALT TBPH SAGE SVRA CMRX KROS RAPP OABI SLDB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
210 East Grand Avenue, South San Francisco, CA, USA, 94080
Website
https://www.allogene.com
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Executives
Earl Martin Douglas officer: GENERAL COUNSEL BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Zachary Roberts officer: EVP of R&D C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
David D Chang director, officer: President and CEO C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Geoffrey M. Parker officer: CHIEF FINANCIAL OFFICER 15 RIORDAN PLACE, MENLO PARK CA 94025
Timothy L. Moore officer: Chief Technical Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Deborah M. Messemer director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Franz B Humer director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Arie Belldegrun director, 10 percent owner UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Yinlin Jack Chen officer: SVP, Finance 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lillian Smith officer: VP, Corporate Counsel 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri officer: General Counsel C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Owen N. Witte director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado officer: EVP of R&D and CMO 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore officer: Chief Technical Officer C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080